Published in Blood Weekly, May 12th, 1997
Novel phenothiazine compounds have been developed to photoinactivate viruses in RBC suspensions, noted Dr. Stephen J. Wagner, Scientist, Product Development Department, Holland Laboratory, American Red Cross, Rockville, Maryland, at the Blood Safety & Screening Conference, sponsored by Cambridge Healthtech Institute, held April 14-16, 1997, in McLean, Virginia.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.